1,041 material Form 8-K filings that 824 companies we cover made with the SEC in November 2025, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Lantheus disclosed that CEO Brian Markison is retiring under agreements dated November 6, 2025. He will receive base salary through December 31, 2025, and will then serve as an advisor from January 1 to March 31, 2026, at $83,333 per month, with the option to extend. The filing says his outstanding equity awards will keep vesting through his retirement date, which matters to shareholders because it defines the transition terms for the company's top executive.
CEO Brian Markison's retirement agreement and consulting agreement are both effective November 6, 2025.
Base salary continues through the retirement date of December 31, 2025.
Advisory fee is $83,333 per month for consulting from January 1, 2026 through March 31, 2026, with the option to extend.
A lump sum equal to his 2025 earned annual cash bonus, if any, will be paid within 60 days of the retirement date.
National HealthCare appointed Dr. Lisa Piercey to its board effective November 6, 2025, and named her to the Audit Committee. The company also said President and COO R. Michael Ussery will retire December 31, 2025, after which CEO Stephen F. Flatt will also serve as president and Timothy J. Shelly will become principal operating officer.
Dr. Lisa Piercey appointed director effective November 6, 2025; independent director and Audit Committee member
Piercey is intended as a nominee for a three-year term at the 2026 Annual Meeting of Shareholders
R. Michael Ussery retires as President and COO effective December 31, 2025
Stephen F. Flatt, CEO since January 1, 2017, will also serve as president; Timothy J. Shelly becomes principal operating officer
Ameriprise Financial appointed Liane J. Pelletier as a director effective November 12, 2025, on the recommendation of its Nominating and Governance Committee. She will also join the Audit and Risk Committee on the same date. The filing describes a routine board addition with no financial results or changes to company operations disclosed.
Liane J. Pelletier appointed director effective November 12, 2025
She joins the Audit and Risk Committee on the same date
She is eligible for a pro rata portion of the $210,000 annual deferred share unit grant through the 2026 annual meeting
Filing states no related-party transactions requiring disclosure under Item 404(a)
Intel's board appointed semiconductor executive Dr. Craig H. Barratt as an independent director on November 10, 2025, effective immediately. The filing describes his experience as chief executive of Atheros Communications and Barefoot Networks, and as a former Intel senior vice president. The filing does not report any financial results or changes to Intel's guidance.
Board appointed Dr. Craig H. Barratt, 63, effective immediately on November 10, 2025, and the Board determined he is independent under Nasdaq rules.
Compensation includes the standard non-employee director cash retainer, pro-rated for the first year, plus restricted stock units valued at approximately $125,000 on the grant date in the first quarter of 2026.
Barratt previously served as CEO of Barefoot Networks, which Intel acquired in 2019, and as Intel senior vice president until 2020.
Barratt also sits on the boards of Intuitive Surgical and Astera Labs.
Baxter International said Executive Vice President and Group President, Pharmaceuticals Alok Sonig notified the company on November 5, 2025, that he will resign effective December 1, 2025, to join a company in the healthcare industry. The filing does not name a successor or describe the reasons beyond the new role, so shareholders will need later disclosures to judge how the departure affects the pharmaceuticals business.
Alok Sonig gave notice of resignation on November 5, 2025.
His resignation as Executive Vice President and Group President, Pharmaceuticals takes effect December 1, 2025.
He is leaving to join a company in the healthcare industry; the filing does not name that company.
Tandem Diabetes Care appointed Sandra Beaver as an independent director effective November 7, 2025, expanding the board from eight to nine members. She will serve on the Audit Committee and the Cybersecurity and Data Privacy Committee, and the filing describes her as a finance executive with more than 20 years of experience.
Sandra Beaver, age 48, appointed to the board effective November 7, 2025, with a term expiring at the 2026 annual meeting
Initial RSU award for 20,242 shares valued at $300,000 under the non-employee director policy
Annual retainer of $60,000 plus $11,000 for Audit Committee and $6,000 for Cybersecurity and Data Privacy Committee service
Disney amended the employment agreement of CFO Hugh F. Johnston on November 10, 2025, extending the term to January 31, 2029. The amendment raises his target long-term equity incentive award to $16,500,000 starting in the current fiscal year, while base salary and target bonus are unchanged.
Employment term extended to January 31, 2029
Target long-term equity incentive annual award raised to $16,500,000, effective current fiscal year
Base salary and target annual bonus opportunity not increased
Terminations on or after December 31, 2026 treated as scheduled expiration for certain January 2025 and fiscal 2026 equity awards
Columbia Sportswear named Peter J. Bragdon and Joseph P. Boyle as co-presidents effective November 12, 2025, as part of an ongoing succession plan. Timothy P. Boyle remains Chairman and CEO, and both co-presidents will report to him. The filing also appoints Richelle T. Luther and Jana C. Humble to senior legal and human resources roles to support the transition.
Peter J. Bragdon becomes President, overseeing all international businesses and the Mountain Hardwear, prAna and SOREL brands, while keeping administrative and international distributor sales oversight.
Joseph P. Boyle becomes President, Columbia Brand, overseeing the Columbia brand including the North America business.
Richelle T. Luther is appointed Executive Vice President, Chief Administrative Officer and General Counsel, and Jana C. Humble is appointed Senior Vice President and Chief Human Resources Officer, both effective November 12, 2025.
Timothy P. Boyle retains the roles of Chairman and CEO; the co-presidents continue to report to him.
Marriott Vacations Worldwide said Brian E. Miller, President, Vacation Ownership, will retire from that role on December 31, 2025, and will advise the CEO through March 27, 2026. Miller is not receiving severance, and the filing states his retiree is not the result of a disagreement with the company.
Miller notified the company on November 10, 2025 of his retirement, effective December 31, 2025.
Miller remains an advisor to the President and CEO through March 27, 2026.
Stephanie Sobeck Butera and John Fitzgerald will report directly to the CEO effective January 1, 2026.
The company said additional organizational changes will be announced at a later date.
Cleveland-Cliffs appointed Edilson Camara as an independent director effective November 12, 2025, and named him to the Compensation and Organization Committee. The filing describes routine nonemployee director pay and an indemnification agreement, with no financial results or change in company strategy disclosed.
Edilson Camara appointed to the Board effective November 12, 2025, and designated independent under NYSE standards
Mr. Camara joins the Compensation and Organization Committee
He will receive a prorated restricted share award under the 2021 Nonemployee Directors' Compensation Plan, plus quarterly retainer fees
The company expects to enter into an indemnification agreement with him, under Ohio law
Creative Medical Technology Holdings' Compensation Committee approved bonuses of $100,000 for CEO Timothy Warbington and $25,000 for CFO Donald Dickerson on November 6, 2025, according to an 8-K filed November 12, 2025. The filing does not state the basis for the bonuses or any performance criteria, and it contains no financial results or changes in officer roles.
Compensation Committee approved the bonuses on November 6, 2025
Champion Homes said Chair and director Eddie Capel resigned from the board on November 10, 2025, effective immediately. The company said the resignation was not due to any disagreement over operations, policies, or practices, and the board reduced its size to seven directors.
Eddie Capel resigned as Chair and board member on November 10, 2025, effective immediately
Resignation was not due to any disagreement with the company or its management
Constellation Energy said director Peter Oppenheimer notified the board on November 9, 2025 of his intent to retire. His retirement takes effect December 31, 2025. The filing contains no financial results, and it does not name a successor.
Peter Oppenheimer notified the board of his intent to retire on November 9, 2025.
Retirement is effective December 31, 2025.
The filing reports no financial results or guidance changes.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.